Idorsia Ltd (IDIA.SW) SIX
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
Idorsia Ltd
Address
Hegenheimermattweg 91
Allschwil, 4123
Switzerland
Phone
41 58 844 10 10
Website
Sector
Healthcare
Industry
Biotechnology
Employees
636
First IPO Date
June 16, 2017
Key Executives
| Name | Title | Pay | Year Born |
| Jean-Paul Clozel | Chairman of the Board & Interim CEO | 145,639 | 1955 |
| Alberto Gimona | Executive Vice President and Head of Global Clinical Development & Medical Affairs | 821,912 | 1960 |
| André C. Muller | Advisor & Director | 1.19M | 1963 |
| Andrew Jones | Senior Vice President, Head of Corporate Communications & Investor Relations | 0 | 1975 |
| Martine Clozel | Executive Vice President, Chief Scientific Officer & Head of Research | 0 | 1955 |
| Arno Groenewoud | Executive Vice President & Chief Financial Officer | 0 | 1971 |
| Amer Joseph | Executive VP, Chief Medical Officer & Head of Global Clinical Development | 0 | N/A |
| Gaby Scherer | Senior Vice President & Head of Global Human Resources | 0 | 1961 |
| Benjamin Limal | President of EUCAN Region | 0 | 1973 |
| Julien Gander | Executive Vice President, Chief Legal & Corporate Development Officer and Company Secretary | 0 | 1979 |
| Olivier Lambert | Senior Vice President & Head of Technical Operations | 0 | 1966 |
Description
Idorsia Ltd is a biopharmaceutical company based in Switzerland, dedicated to the discovery, development, and commercialization of innovative medicines that address significant unmet medical needs. The company maintains a diverse clinical development pipeline, with therapeutic focuses spanning central nervous system (CNS), cardiovascular, and immunological disorders, as well as various orphan diseases. Idorsia engages in several strategic collaborations: A partnership with Janssen Biotech Inc. for the joint development and commercialization of aprocitentan and its related compounds or products. A licensing agreement with Mochida Pharmaceutical covers the supply, co-development, and co-marketing of daridorexant. The company collaborates with Hoffman-La Roche Inc. to develop and market compounds within the field of cancer immunotherapy. An alliance with Antares Pharma, Inc. focuses on the creation of a self-administered drug delivery system for Selatogrel. A partnership with Neurocrine Biosciences, Inc. is in place for the development and commercialization of ACT-709478, an epilepsy treatment currently in Phase II clinical trials. Idorsia Ltd was founded in 2017 and its corporate headquarters are situated in Allschwil, Switzerland.
